RATIONALE: Shorter survival in heritable pulmonary arterial hypertension (HPAH), often due to BMPR2 mutation, has been described in association with impaired right ventricle (RV) compensation. HPAH animal models are insulin resistant, and cells with BMPR2 mutation have impaired fatty acid oxidation, but whether these findings affect the RV in HPAH is unknown. OBJECTIVES: To test the hypothesis that BMPR2 mutation impairs RV hypertrophic responses in association with lipid deposition. METHODS: RV hypertrophy was assessed in two models of mutant Bmpr2 expression, smooth muscle-specific (Sm22(R899X)) and universal expression (Rosa26(R899X)). Littermate control mice underwent the same stress using pulmonary artery banding (Low-PAB). Lipid content was assessed in rodent and human HPAH RVs and in Rosa26(R899X) mice after metformin administration. RV microarrays were performed using human HPAH and control subjects. RESULTS: RV/(left ventricle + septum) did not rise directly in proportion to RV systolic pressure in Rosa26(R899X) but did in Sm22(R899X) (P < 0.05). Rosa26(R899X) RVs demonstrated intracardiomyocyte triglyceride deposition not present in Low-PAB (P < 0.05). RV lipid deposition was identified in human HPAH RVs but not in controls. Microarray analysis demonstrated defects in fatty acid oxidation in human HPAH RVs. Metformin in Rosa26(R899X) mice resulted in reduced RV lipid deposition. CONCLUSIONS: These data demonstrate that Bmpr2 mutation affects RV stress responses in a transgenic rodent model. Impaired RV hypertrophy and triglyceride and ceramide deposition are present as a function of RV mutant Bmpr2 in mice; fatty acid oxidation impairment in human HPAH RVs may underlie this finding. Further study of how BMPR2 mediates RV lipotoxicity is warranted.
RATIONALE: Shorter survival in heritable pulmonary arterial hypertension (HPAH), often due to BMPR2 mutation, has been described in association with impaired right ventricle (RV) compensation. HPAH animal models are insulin resistant, and cells with BMPR2 mutation have impaired fatty acid oxidation, but whether these findings affect the RV in HPAH is unknown. OBJECTIVES: To test the hypothesis that BMPR2 mutation impairs RV hypertrophic responses in association with lipid deposition. METHODS: RV hypertrophy was assessed in two models of mutant Bmpr2 expression, smooth muscle-specific (Sm22(R899X)) and universal expression (Rosa26(R899X)). Littermate control mice underwent the same stress using pulmonary artery banding (Low-PAB). Lipid content was assessed in rodent and human HPAH RVs and in Rosa26(R899X) mice after metformin administration. RV microarrays were performed using human HPAH and control subjects. RESULTS: RV/(left ventricle + septum) did not rise directly in proportion to RV systolic pressure in Rosa26(R899X) but did in Sm22(R899X) (P < 0.05). Rosa26(R899X) RVs demonstrated intracardiomyocyte triglyceride deposition not present in Low-PAB (P < 0.05). RV lipid deposition was identified in human HPAH RVs but not in controls. Microarray analysis demonstrated defects in fatty acid oxidation in human HPAH RVs. Metformin in Rosa26(R899X) mice resulted in reduced RV lipid deposition. CONCLUSIONS: These data demonstrate that Bmpr2 mutation affects RV stress responses in a transgenic rodent model. Impaired RV hypertrophy and triglyceride and ceramide deposition are present as a function of RV mutant Bmpr2 in mice; fatty acid oxidation impairment in human HPAH RVs may underlie this finding. Further study of how BMPR2 mediates RV lipotoxicity is warranted.
Authors: R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle Journal: Eur Respir J Date: 2008-12-01 Impact factor: 16.671
Authors: Gustavo A Heresi; Metin Aytekin; Jennie Newman; Joseph DiDonato; Raed A Dweik Journal: Am J Respir Crit Care Med Date: 2010-05-06 Impact factor: 21.405
Authors: Evan L Brittain; Meredith E Pugh; Lisa A Wheeler; Ivan M Robbins; James E Loyd; John H Newman; Emma K Larkin; Eric D Austin; Anna R Hemnes Journal: Pulm Circ Date: 2013-12-03 Impact factor: 3.017
Authors: Gopinath Sutendra; Sebastien Bonnet; Gael Rochefort; Alois Haromy; Karalyn D Folmes; Gary D Lopaschuk; Jason R B Dyck; Evangelos D Michelakis Journal: Sci Transl Med Date: 2010-08-11 Impact factor: 17.956
Authors: John R Ussher; Clifford D L Folmes; Wendy Keung; Natasha Fillmore; Jagdip S Jaswal; Virgilio J Cadete; Donna L Beker; Victoria H Lam; Liyan Zhang; Gary D Lopaschuk Journal: PLoS One Date: 2012-05-22 Impact factor: 3.240
Authors: Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West Journal: Eur Respir J Date: 2017-08-03 Impact factor: 16.671
Authors: Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-07-31 Impact factor: 5.464
Authors: Ling Yan; Xinping Chen; Megha Talati; Bethany Womack Nunley; Santhi Gladson; Tom Blackwell; Joy Cogan; Eric Austin; Ferrin Wheeler; James Loyd; James West; Rizwan Hamid Journal: Am J Respir Crit Care Med Date: 2016-04-15 Impact factor: 21.405
Authors: Xinping Chen; Megha Talati; Joshua P Fessel; Anna R Hemnes; Santhi Gladson; Jaketa French; Sheila Shay; Aaron Trammell; John A Phillips; Rizwan Hamid; Joy D Cogan; Elliott P Dawson; Kristie E Womble; Lora K Hedges; Elizabeth G Martinez; Lisa A Wheeler; James E Loyd; Susan J Majka; James West; Eric D Austin Journal: Circulation Date: 2015-10-20 Impact factor: 29.690
Authors: Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Ke Yuan; Ning-Yi Shao; Jan K Hennigs; Marielle Discipulo; Mark E Orcholski; Elya Shamskhou; Alice Richter; Xinqian Hu; Joseph C Wu; Vinicio A de Jesus Perez Journal: Am J Pathol Date: 2016-07-25 Impact factor: 4.307